

Autophagy is involved in neurofibromatosis type I gene-modulated osteogenic differentiation in human bone mesenchymal stem cells

YIQIANG LI, MINGWEI ZHU, XUEMEI LIN, JINGCHUN LI, ZHE YUAN, YANHAN LIU and HONGWEN XU

Department of Pediatric Orthopedics, Guangzhou Women and Children's Medical Center,
Guangzhou Medical University, Guangzhou, Guangdong 510623, P.R. China

Received October 25, 2020; Accepted July 14, 2021

DOI: 10.3892/etm.2021.10697

Abstract. Neurofibromatosis type I (NF1) is an autosomal dominant genetic disease that is caused by mutations in the *NF1* gene. Various studies have previously demonstrated that the mTOR complex 1 signaling pathway is essential for the *NF1*-modulated osteogenic differentiation of bone mesenchymal stem cells (BMSCs). Additionally, the mTOR signaling pathway plays a notable role in autophagy. The present study hypothesized that *NF1* could modulate the osteogenic differentiation of BMSCs by regulating the autophagic activities of BMSCs. In the present study, human BMSCs were cultured in an osteogenic induction medium. The expression of the *NF1* gene was either knocked down or overexpressed by transfection with a specific small interfering RNA (siRNA) targeting *NF1* or the pcDNA3.0 *NF1*-overexpression plasmid, respectively. Autophagic activities of BMSCs (Beclin-1, P62, LC3B I, and LC3B II) were determined using western blotting, electron microscopy, acridine orange (AO) staining and autophagic flux/lysosomal detection by fluorescence microscopy. In addition, the autophagy activator rapamycin (RAPA) and inhibitor 3-methyladenine (3-MA) were used to investigate the effects of autophagy on *NF1*-modulated osteogenic differentiation in BMSCs. Inhibiting *NF1* with siRNA significantly decreased the expression levels of autophagy markers Beclin-1 and LC3B-II, in addition to osteogenic differentiation markers osterix, runt-related

transcription factor 2 and alkaline phosphatase. By contrast, overexpressing *NF1* with pcDNA3.0 significantly increased their levels. Transmission electron microscopy, AO staining and autophagic flux/lysosomal detection assays revealed that the extent of autophagosome formation was significantly decreased in the *NF1*-siRNA group but significantly increased in the *NF1*-pcDNA3.0 group when compared with the NC-siRNA and pcDNA3.0 groups, respectively. In addition, the activity of the PI3K/AKT/mTOR pathway [phosphorylated (p)-PI3K, p-AKT, p-mTOR and p-p70S6 kinase] was significantly upregulated in the *NF1*-siRNA group compared with the NC-siRNA group, and significantly inhibited in the *NF1*-pcDNA3.0 group, compared with the pcDNA3.0 group. The knockdown effects of *NF1*-siRNA on the autophagy and osteogenic differentiation of BMSCs were reversed by the autophagy activator RAPA, while the overexpression effects of *NF1*-pcDNA3.0 on the autophagy and osteogenic differentiation of BMSCs were reversed by the autophagy inhibitor 3-MA. In conclusion, results from the present study suggest at the involvement of autophagy in the *NF1*-modulated osteogenic differentiation of BMSCs. Furthermore, *NF1* may partially regulate the autophagic activity of BMSCs through the PI3K/AKT/mTOR signaling pathway.

Introduction

Neurofibromatosis type I (NF1) is an autosomal dominant genetic disorder caused by mutations in the *NF1* gene (1-3). The reported incidence of NF1 varies from 1/2,500 to 1/3,500 individuals worldwide (1-3). The clinical manifestations of NF1 are varied and include cafe-au-lait spots, hamartomas of the iris and skeletal abnormalities (2,4). It has been reported that 50% patients with NF1 have associated skeletal abnormalities, including long bone dysplasia, sphenoid wing dysplasia, scoliosis and congenital pseudarthrosis of the tibia (5,6).

Although mutations in the *neurofibromin* (*NF1*) gene are considered to be the primary cause of the occurrence of NF1 (1,7), the mechanism underlying the formation of skeletal abnormalities associated with *NF1* is still not fully understood. The *NF1* gene encodes a Ras GTPase that consists of 2,818 amino acids (1). Mutations in *NF1* lead to the functional deficiency of neurofibromin and hyperactivation

Correspondence to: Dr Hongwen Xu or Dr Yiqiang Li, Department of Pediatric Orthopedics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou, Guangdong 510623, P.R. China
E-mail: xuhongwen@gwcmc.org
E-mail: liyiq@gwcmc.org

Abbreviations: AO, acridine orange; 3-MA, 3-methyladenine; ALP, alkaline phosphatase; BMSCs, bone mesenchymal stem cells; mTORC1, mammalian target of rapamycin complex 1; NF1, neurofibromatosis type I; RAPA, rapamycin

Key words: neurofibromatosis type I, bone marrow stem cells, osteogenic differentiation, autophagy, PI3K/AKT/mTOR pathway

of p21-Ras (1,7). In addition, NF1 has been documented to regulate bone mesenchymal stem cell, neuronal, and glial cell proliferation, differentiation and survival (1).

Previous studies have demonstrated the existence of significantly impaired osteogenic differentiation in human bone mesenchymal stem cells (BMSCs) in patients with NF1-associated skeletal abnormalities (8,9). Furthermore, abnormal osteoblast differentiation and proliferation have been reported to occur due to the loss of *NF1* function (10-12). A previous study showed that the *NF1* gene can modulate the proliferation and osteogenic differentiation of BMSCs (13). In addition, it has been demonstrated that inhibiting the expression of *NF1* can activate mTOR complex 1 (mTORC1) signaling and subsequently inhibit the osteogenic differentiation of BMSCs (13).

Autophagy is an evolutionarily conserved adaptive response that takes part in numerous physiological and pathological processes (14). Previous studies have reported that autophagy serves an important role in the osteogenic differentiation of BMSCs (15,16). The PI3K/AKT/mTOR pathway is an important signaling pathway that is involved in the regulation of signal transduction and biological processes, such as cell proliferation, differentiation, apoptosis, metabolism and angiogenesis (17). The PI3K/AKT/mTOR pathway is also considered to be a classical signaling pathway for autophagy activation (18), such that mTORC1 is the main gatekeeper to autophagy that connects environmental cues to metabolic processes in order to preserve cellular homeostasis (19). In a recent study, Tan *et al* (20) revealed that overexpression of *NF1* gene enhanced the osteogenic differentiation of BMSCs by promoting autophagy and that mTORC1 signaling was involved in this process. However, this previous study only established *NF1*-overexpression BMSC models, which is different from the clinical situation in patients with *NF1*, where the function of the *NF1* gene is typically insufficient (20). Therefore, a cell model with the inhibited expression of *NF1* would simulate the pathological conditions of *NF1* more closely compared with one modeling the overexpression of *NF1*.

The present study established cell models of BMSCs that with reduced *NF1* expression or overexpressed *NF1*, similar to the protocol followed in a previous study (13). To investigate the effect of autophagy on the osteogenic differentiation of BMSCs, a classical autophagy inhibitor 3-methyladenine (3-MA) and a specific mTOR inhibitor rapamycin (RAPA), were used. The aims of the present study were as follows: i) To evaluate the effect of *NF1* on the autophagy of BMSCs; ii) to investigate the effect of autophagy on *NF1*-modulated osteogenic differentiation of BMSCs; and iii) to verify the effect of the PI3K/AKT/mTOR signaling pathway on *NF1*-mediated regulation of BMSC autophagy.

Materials and methods

Culture of human BMSCs. BMSCs were purchased from the American Type Culture Collection (cat. no. CRL-3421). They were cultured in Human Bone Marrow Mesenchymal Stem Cell Basal Medium (Cyagen Biosciences, Inc.) supplemented with 10% qualified FBS (Takara Bio, Inc.), 10% glutamine and 10% penicillin-streptomycin at 37°C in a humidified atmosphere with 5% CO₂ for 14 days (13). The standard

procedure to induce osteogenic differentiation of BMSCs is by culturing cells in Human Mesenchymal Stem Cell Osteogenic Differentiation Basal Medium (Cyagen Biosciences, Inc.) containing 10% FBS (Takara Bio, Inc.), 0.2% ascorbate acid (Shanghai Aladdin Biochemical Technology Co., Ltd.), 0.01% dexamethasone (Shanghai Aladdin Biochemical Technology Co., Ltd.), 1% glutamine, 100 units of penicillin/streptomycin and 1% β -glycerophosphate sodium (13).

Cell transfection and treatment. BMSC models with inhibited or overexpressed *NF1* were established using a method similar to that used by a previous study (13). Briefly, a small interfering RNA (siRNA) targeting *NF1* and a negative control (NC) siRNA (non-targeting sequence) were purchased from Shanghai GenePharma Co., Ltd. The siRNA targeting sequences were as follows: *NF1*-siRNA, 5'-ACATACCAAAGTCAGTAC T-3'; and NC-siRNA, 5'-AACAAGATGAAGAGCACCA-3'. Human BMSCs were grown in 6/12-well culture plates until ~80% confluence, then transfected with 100 nm siRNA-*NF1* or NC-siRNA for 48 h at 37°C using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). Human *NF1* cDNA was amplified by PCR and inserted into pcDNA3.0 (*NF1*-pcDNA3.0; Invitrogen; Thermo Fisher Scientific, Inc.). Then *NF1*-pcDNA3.0 (1/2 μ g) or pcDNA3.0 (1/2 μ g) was transfected into BMSCs using Lipofectamine® 2000 in accordance with the manufacturer's protocol. Twenty-four hours later, the transfected cells were divided into the following four groups: NC-siRNA, *NF1*-siRNA, pcDNA3.0 and *NF1*-pcDNA3.0. Additionally, a control group was established containing untransfected BMSCs. The transfected BMSCs were treated with 50 nM RAPA (cat. no. AY 22989; MedChemExpress) or 5 mM 3-MA (cat. no. S2767-1; Selleck Chemicals) for 24 h at 37°C for the detection of autophagy and associated pathways. The concentrations used in the present study were based on those used in previous studies (21,22). In addition, osteogenic differentiation experiments were conducted on day 14 following transfection.

RNA extraction and reverse transcription-quantitative PCR (RT-qPCR). Following transfection and differentiation on day 14, total RNA was isolated from cultured cells using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. Gene expression levels were measured in a real-time PCR detection system (Bio-Rad Laboratories, Inc.) by SYBR® Green (Bio-Rad Laboratories, Inc.) detection. Briefly, the extracted RNA was reverse transcribed in the presence of a poly (A) polymerase with an oligo-dT adaptor, using the PrimeScript™ RT Reagent kit with gDNA Eraser (Perfect Real Time; cat. no. RR047A; Takara Bio, Inc.), according to the manufacturer's protocol. The thermocycling conditions were as follows: 42°C for 2 min; followed by 37°C for 15 min and 85°C for 5 sec. The expression of *NF1*, runt-related transcription factor 2 (*Runx2*), alkaline phosphatase (ALP) and Osterix were quantified by qPCR using TB Green® Fast qPCR Mix (cat. no. RR430; Takara Bio, Inc.). Thermocycling conditions were as follows: Initial denaturation at 95°C for 15 min; followed by 40 cycles of 95°C for 15 sec, annealing 50-60°C for 30 sec, 72°C for 30 sec; followed by final extension at 72°C for 7 min. GAPDH was used as the internal control. The PCR primers are listed

Table I. Primers used in the present study.

ID	Orientation	Sequence (direction, 5'-3')
NF1	F	GTATTGAATTGAAGCACCTTTGTTTG
NF1	R	CTGCCCCAAGGCTCCCCCAG
ALP	F	CCAACTCTTTTGTGCCAGAGA
ALP	R	GGCTACATTGGTGTGAGCTTTT
Runx2	F	GACTGTGGTTACCGTCATGGC
Runx2	R	ACTTGGTTTTTTCATAACAGCGGA
Osterix	F	ACCTACCC ATCTGACTTTGCTC
Osterix	R	CTGCCCCACTATTTCCCACTG
GAPDH	F	AGGTCGGTGTGAACGGATTG
GAPDH	R	GGGGTCGTTGATGGCAACA

NF1, neurofibromatosis type I; ALP, alkaline phosphatase; Runx2, runt-related transcription factor 2; F, forward; R, reverse.

in Table I. The Cq value obtained for the gene of interest was normalized to that of the housekeeping gene GAPDH to obtain the ΔCq value. The $\Delta\Delta Cq$ value was then obtained by subtracting the ΔCq value for each gene of interest from the ΔCq value for the control sample. The results were calculated using the equation $RQ=2^{-\Delta\Delta Cq}$, where RQ is the relative quantity and is expressed as the fold-change relative to the corresponding gene expression level in the control sample (23).

Western blotting. Transfected and treated BMSC proteins were extracted using lysis buffer containing 50 mM Tris (pH 7.6), 150 mM NaCl, 1% Triton X-100, 1% deoxycholate, 0.1% SDS, 1 mM PMSF and 0.2% aprotinin (Beyotime Institute of Biotechnology). A BCA™ Protein Assay kit (Pierce; Thermo Fisher Scientific, Inc.) was used for quantification of protein samples. Equal amounts of protein samples (30 μ g per lane) were separated on 15% SDS-PAGE gels and transferred onto PVDF membranes. After blocking in 5% BSA serum (Roche Diagnostics GmbH) for 1 h at 37°C, the blocked membranes were incubated with the corresponding primary antibodies overnight at 4°C. The membranes were then washed in Tris-buffered saline (Tris 20 mM, NaCl 137 mM, pH 7.6) containing 0.1% Tween-20 (TBST; cat. no. P2287; Sigma-Aldrich; Merck KGaA) three times and incubated for 1 h at room temperature with appropriate secondary antibodies conjugated to horseradish peroxidase (HRP). The membranes were incubated with ECL reagent (Immun-Star HRP Substrate kit; cat. no. 1705040; Bio-Rad Laboratories, Inc.). The signals were then visualized and analyzed using Image Lab™ software 5.2 (Bio-Rad Laboratories, Inc.). For the present study, primary antibodies against *NF1* (1:1,000; cat. no. ab128054; Abcam), Beclin-1 (1:1,000; cat. no. ab210498; Abcam), p62 (1:1,000; cat. no. ab109012; Abcam), LC3BI/II (1:1,000; cat. no. ab192890; Abcam), GAPDH (1:1,000; cat. no. ab8245; Abcam), ALP (1:1,000; cat. no. ab229126; Abcam), Runx2 (1:1,000; cat. no. ab236639; Abcam) and Osterix (1:1,000; cat. no. ab209484; Abcam) were used. Antibodies against phosphorylated (p)-mTOR (1:1,000; cat. no. 5536; Cell Signaling Technology), total (t)-mTOR (1:1,000; cat. no. 2983; Cell Signaling Technology),

p-p70S6 kinase (p70S6K; 1:1,000; cat. no. 9204; Cell Signaling Technology), t-p70S6K (1:1,000; cat. no. 2708; Cell Signaling Technology), AKT (1:1,000; cat. no. 9272; Cell Signaling Technology), p-AKT (1:1,000; cat. no. 4060; Cell Signaling Technology), PI3K (1:1,000; cat. no. 4249; Cell Signaling Technology) and p-PI3K (1:1,000; cat. no. 17366; Cell Signaling Technology) were also used. HRP-conjugated anti-mouse IgG (1:5,000; cat. no. ab6728; Abcam) and HRP-conjugated anti-rabbit IgG (1:5,000; cat. no. ab6721; Abcam) were used as secondary antibodies.

Acridine orange (AO) staining. After conditioning, BMSCs were harvested and suspended in PBS at 1×10^6 cells/ml. Next, 95 μ l of this cell suspension was considered and 5 μ l AO staining solution (Sigma-Aldrich; Merck KGaA) was added. The reaction was allowed to proceed for 10 min in the dark at room temperature. Subsequently, 5 ml PBS was added and the suspension was then centrifuged on a conventional centrifuge at 150 x g at room temperature for 5 min. The supernatant was then discarded and washed twice with PBS. The cells suspended in PBS were pipetted onto slides and sealed with cover glass. Autophagy was visualized under a fluorescence microscope (magnification, x40; Leica DMIRB; Leica Microsystems GmbH).

Autophagic flux/lysosomal detection. To track and observe the formation of autophagosomes and autophagic flux, 1×10^6 cells/ml were grown to ~80% confluence, infected with Ad-GFP-LC3B (cat. no. C3006; Beyotime Institute of Biotechnology) at $7 \log_{10}$ PFU/ml for 24 h and cultured in a 6-well plate on cover glass to monitor autophagy flux. Furthermore, the slides were washed with PBS and 3% paraformaldehyde was added into each well. The plate was then placed in the dark for 20 min at room temperature. The slides were washed three times with PBS before 2 ml PBS was then added to each well. The plate was incubated with shaking at room temperature for 10 min. The coverslips were mounted with an anti-fade mounting solution (cat. no. P0126; Beyotime Institute of Biotechnology) and dried for 1 min at room temperature. Subsequently, the slides were observed with a fluorescence microscope

(magnification, x40; Leica DMIRB; Leica Microsystems GmbH). During this procedure, GFP-LC3 was combined with autophagosomes, and detected using fluorescence microscopy. Under the fluorescence microscope, the GFP-LC3 combined autophagosomes were indicated by granular green fluorescence.

ALP staining. BMSCs were inoculated into a 12-well culture plate at a density of 1×10^4 cells per well at 37°C in 5% CO_2 . After 24 h, the medium was replaced with the osteogenic induction medium (cat. no. CTCC-Y001, PH Biomedicine) and cultured at 37°C in 5% CO_2 . The medium was changed every 2-3 days and removed after 14 days. The cells were washed twice with PBS and fixed with 4% paraformaldehyde for 30 min at room temperature. The paraformaldehyde was then removed and the cells were washed three times with ddH_2O and an ALP staining solution (Shanghai Gefan Biotechnology Co., Ltd.) was added for 30 min at room temperature. The ALP staining solution was removed, the cells were washed three times with ddH_2O and visualized under a microscope (magnification, x40; Leica DMIRB; Leica Microsystems GmbH); in addition, images were captured.

Alizarin red staining. BMSCs were cultured with osteogenic induction medium for 14 days before examination of Alizarin red staining. The culture medium was discarded and the cells (1×10^6) were fixed with 4% paraformaldehyde for 15-20 min at room temperature, following which they were washed three times with PBS. Alizarin red staining solution (ScienCell Research Laboratories, Inc.) was prepared in advance and was added to the culture plate and placed in the incubator for 15 min at room temperature. The staining solution was then discarded, the plate was washed three times with PBS solution and placed under a differential interference contrast microscope (magnification, x40; Leica DMIRB; Leica Microsystems GmbH) to capture images.

Transmission electron microscopy. BMSCs were cultured in 6-well plates and transfected with *NF1*-pcDNA3.0 for 48 h, and then collected and fixed with a mixture of 2.5% glutaraldehyde and 1% acetic acid for 2 h at room temperature. Samples were then processed following a standard protocol (24). Briefly, samples were dehydrated using ethanol, stained for 2 h using uranyl acetate and alkaline lead citrate at room temperature, embedded using Epon resin at 37°C overnight, and cut into 500 nm-thick sections using an automatic microwave sample processor (Leica EM AMW; Leica Microsystems GmbH) at room temperature. Observation and imaging were then performed by using a JEM-1400 transmission electron microscope (JEOL, Ltd.).

Statistical analysis. All experiments were repeated \geq three times. The results are expressed as the mean \pm standard deviation. Data were processed using the SPSS 10.0 statistical software (SPSS, Inc.). For between-group comparisons, data were analyzed using an unpaired Student's t-test. One-way analysis of variance followed by a post hoc test of LSD was used to analyze the data among the three groups. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

NF1 regulates the autophagic activity of BMSCs. To detect the effect of *NF1* on the autophagic activity of BMSCs, cell models of BMSCs with *NF1* knockdown using *NF1*-siRNA or *NF1* overexpression (*NF1*-pcDNA3.0) were established. RT-qPCR and western blotting results showed that the mRNA (Fig. 1A) and protein (Fig. 1B and C) expression levels of *NF1* were significantly decreased in the *NF1*-siRNA group compared with those in NC siRNA, but significantly increased in the *NF1*-pcDNA3.0 group compared with those in the pcDNA3.0 group. Western blotting results indicated that in the *NF1*-siRNA group, the expression of Beclin-1 was significantly decreased, whereas that of LC3B-I and p62, a marker of autophagosome degradation (25), were significantly increased compared with that in the NC siRNA group (Fig. 1B and C). In addition, in the *NF1*-pcDNA3.0 group, the expression of autophagy markers Beclin-1, was significantly increased, whereas that of LC3B-I and p62 was significantly decreased compared with that in the pcDNA3.0 group (Fig. 1B and C).

Furthermore, autophagic activity was detected using transmission electron microscopy. The results revealed that overexpression of *NF1* (*NF1*-pcDNA3.0) increased the formation of autophagosomes, whilst inhibiting the expression of *NF1* (*NF1*-siRNA) significantly reduced the formation of autophagosomes when compared with groups pcDNA3.0 and NC-siRNA, respectively (Fig. 2). Furthermore, AO staining and autophagic flux/lysosomal detection were performed (Fig. 3A). AO staining demonstrated that the formation of autophagolysosomes (indicated by yellow-red or orange fluorescence in Fig. 3A) was increased in the *NF1*-pcDNA3.0 group but decreased in the *NF1*-siRNA group when compared with groups NC-siRNA and pcDNA3.0. The autophagic flux/lysosomal detection assay also revealed similar results (Fig. 3B). During the formation of autophagosomes, GFP-LC3 protein transferred to the membrane of autophagosomes, and the autophagosomes were indicated by green puncta using fluorescence microscopy. The results of the present study indicated that the autophagic flux/lysosomal was significantly increased in the *NF1*-pcDNA3.0 group but decreased in the *NF1*-siRNA group when compared with the pcDNA3.0 and NC-siRNA groups, respectively.

Collectively, these results suggest that overexpression of *NF1* promoted autophagic activity of BMSCs, whilst knock-down of *NF1* expression decreased the level of autophagy in BMSCs.

NF1 modulates osteogenic differentiation by influencing the autophagic activity of BMSCs. The results of RT-qPCR and western blotting indicated that the expression levels of osteogenic differentiation markers Osterix, Runx2 and ALP were markedly decreased in the *NF1*-siRNA group, whereas they were increased in the *NF1*-pcDNA3.0 group compared with those in the NC siRNA group (Fig. 4A-D). To investigate the effects of autophagy on osteogenic differentiation of BMSCs, an activator (RAPA) and inhibitor (3-MA) of autophagy were added to the *NF1*-siRNA and *NF1*-pcDNA3.0 groups, respectively. As a result, the levels of the osteogenic differentiation markers Osterix, Runx2 and ALP increased markedly in the RAPA-treated group compared with that in




Figure 1. *NF1* regulates the autophagic activity of bone mesenchymal stem cells. (A) Reverse transcription-quantitative PCR demonstrated significant down-regulation of *NF1*-mRNA expression in the *NF1*-siRNA group and upregulation of *NF1*-mRNA expression in the *NF1*-pcDNA3.0 group. (B) Western blotting and subsequent (C) quantification indicated that the protein levels of *NF1*, Beclin-1 were significantly decreased in the *NF1*-siRNA group and increased in the *NF1*-pcDNA3.0 group, whereas the changes in the expression of p62 and LC3B-I revealed the opposite pattern. * $P < 0.05$ vs. NC-siRNA; # $P < 0.05$ vs. *NF1*-pcDNA3.0. *NF1*, neurofibromin-1; si-, small interfering; NC, negative control.




Figure 2. Transmission electron microscopy results. It demonstrated that the formation of autophagosomes was decreased in the *NF1*-siRNA group and increased in the *NF1*-pcDNA3.0 group (indicated by the arrows). Scale bars, 2 μ m. NC, negative control; si-, small interfering; *NF1*, neurofibromin-1.




Figure 3. AO staining and autophagic flux detection from the Ad-GFP-LC3 visualized under a fluorescence microscope. (A) AO staining, autophagolysosomes were stained orange (indicated by white arrows), (B) GFP-LC3 combined autophagosomes were indicated by granular green fluorescence (indicated by the white arrows). Magnification, x200. AO, acridine orange; *NF1*, neurofibromin-1; si-, small interfering; NC, negative control.




Figure 4. Autophagy serves a notable role in *NF1*-modulated osteogenic differentiation of bone mesenchymal stem cells. Expression levels of osteogenic markers (A) Osterix, (B) Runx2 and (C) ALP measured by reverse transcription-quantitative PCR. (D) Western blotting indicated that the expression levels of these markers were markedly decreased in the *NF1*-siRNA group and increased in the *NF1*-pcDNA3.0 group. (A-D) Treatment with RAPA and 3-MA markedly but partially reversed the effects of *NF1*-siRNA and *NF1*-pcDNA3.0 transfection, respectively. *NF1*, neurofibromin-1; si-, small interfering; NC, negative control; Runx2, runt-related transcription factor 2; ALP, alkaline phosphatase; RAPA, rapamycin; 3-MA, 3-methyladenine; *** $P < 0.05$ vs. all other groups; ### $P < 0.05$ vs. all other groups; ** $P < 0.05$ vs. *NF1*-siRNA; ## $P < 0.05$ vs. *NF1*-pcDNA3.0.

the *NF1*-siRNA group alone. By contrast, the expression levels decreased markedly in the 3-MA-treated group compared with those in *NF1*-pcDNA3.0 group alone (Fig. 4A-D).

ALP staining indicated that ALP activity was decreased by knocking down *NF1* expression (*NF1*-siRNA) and increased by *NF1* overexpression (*NF1*-pcDNA3.0) when compared




Figure 5. Results of ALP staining. Activity of ALP was markedly decreased in the *NF1*-siRNA group and increased in the *NF1*-pcDNA3.0 group when compared with NC-siRNA and pcDNA3.0 groups, respectively. However, treatment with RAPA and 3-MA reversed the effects of *NF1*-siRNA and *NF1*-pcDNA3.0 transfection, respectively. Scale bars, 50 μ m. *NF1*, neurofibromin-1; si-, small interfering; NC, negative control; ALP, alkaline phosphatase; RAPA, rapamycin; 3-MA, 3-methyladenine.




Figure 6. Alizarin red staining. Calcium deposition was decreased in the *NF1*-siRNA group and increased in the *NF1*-pcDNA3.0 group when compared with NC-siRNA and pcDNA3.0 groups, respectively. Treatment with RAPA and 3-MA reversed the effects of *NF1*-siRNA and *NF1*-pcDNA3.0 transfection, respectively. Scale bars, 50 μ m. *NF1*, neurofibromin-1; si-, small interfering; NC, negative control; RAPA, rapamycin; 3-MA, 3-methyladenine.

with NC-siRNA and pcDNA3.0 groups, respectively. In addition, RAPA and 3-MA treatment reversed the changes in ALP activity in the *NF1*-siRNA and *NF1*-pcDNA3.0 groups, respectively (Fig. 5). Alizarin red staining, representing calcium deposition, also revealed similar results (Fig. 6). After application of RAPA and 3-MA, the decreased and increased calcium deposition in the *NF1*-siRNA and *NF1*-pcDNA3.0 groups, respectively, were restored to the levels in the control groups (Fig. 6). These results suggest that *NF1* could modulate the osteogenic differentiation of BMSCs by regulating the autophagic activity of BMSCs.

NF1 partially regulates the autophagic activity of BMSCs via the PI3K/AKT/mTOR pathway. The present study verified whether *NF1* could regulate autophagy in BMSCs through the PI3K/AKT/mTOR pathway. Western blotting

results demonstrated that the PI3K/AKT/mTOR pathway was significantly activated in the *NF1*-siRNA group, as indicated by increased levels of p-PI3K, p-AKT, p-mTOR and p-p70S6K compared with those in the NC-siRNA group (Fig. 7A-C). By contrast, the PI3K/AKT/mTOR pathway was significantly inhibited in the *NF1*-pcDNA3.0 group, as indicated by decreased levels of p-PI3K, p-AKT, p-mTOR and p-p70S6K compared with those in the pcDNA3.0 group (Fig. 7A-C). RAPA was used to activate whereas 3-MA was used to inhibit the autophagy of BMSCs in the *NF1*-siRNA and *NF1*-pcDNA3.0 groups, respectively. The results of western blot analysis indicated that the autophagic activity was significantly increased in group *NF1*-siRNA+RAPA and decreased in group *NF1*-pcDNA3.0+3-MA, compared with the *NF1*-siRNA and group *NF1*-pcDNA3.0, respectively (Fig. 7D-F). Transmission electron microscopy, AO staining




Figure 7. *NF1* regulates autophagy in bone mesenchymal stem cells by inhibiting the PI3K/AKT/mTOR pathway. (A-C) Western blotting demonstrated that *NF1*-siRNA significantly decreased the expression of Beclin-1 and LC3B-II and increased the expression of P62 and LC3B-I, while RAPA reversed the effects of *NF1*-siRNA. *NF1*-pcDNA3.0 significantly increased the expression of Beclin-1 and LC3B-II while decreased the expression of P62 and LC3B-I, while 3-MA reversed the effects of *NF1*-pcDNA3.0. (D-F) Western blotting indicated that the levels of proteins in the PI3K/AKT/mTOR pathway (p-PI3K, p-AKT, p-mTOR and p-P70S6K) were upregulated in the *NF1*-siRNA group and downregulated in the *NF1*-pcDNA3.0 group when compared with groups NC-siRNA and pcDNA3.0, respectively. RAPA downregulated PI3K/AKT/mTOR pathway in BMSCs with *NF1*-siRNA, while 3-MA upregulated PI3K/AKT/mTOR pathway in BMSCs with *NF1*-pcDNA3.0. Quantified levels of (B) Beclin-1, (C) p62, LC3B-I, LC3B-II, (E, F) p-PI3K, p-AKT, p-mTOR and p-P70S6K. *P<0.05 vs. pcDNA3.0; **P<0.05 vs. NC-siRNA; #P<0.05 vs. *NF1*-siRNA; &P<0.05 vs. *NF1*-pcDNA3.0. *NF1*, neurofibromatosis type 1; si-, small interfering; NC, negative control; RAPA, rapamycin; 3-MA, 3-methyladenine; p-, phosphorylated; P70S6K, p70S6 kinase.

and autophagic flux/lysosomal detection indicated that the formation of autophagosomes were significantly increased in the *NF1*-siRNA + RAPA group compared with the *NF1*-siRNA, whilst it was significantly decreased in the *NF1*-pcDNA3.0 + 3-MA group compared with that in the *NF1*-pcDNA3.0 group (Figs. 8 and 9). The levels of p-mTOR, p-p70S6K, p-PI3K, and p-AKT were significantly decreased in the *NF1*-siRNA + RAPA group compared with those in the *NF1*-siRNA group (Fig. 7A-C). Additionally, the levels of p-PI3K, p-AKT, p-mTOR and p-p70S6K were all significantly decreased in the *NF1*-pcDNA3.0 + 3-MA group compared with those in the *NF1*-pcDNA3.0 group (Fig. 7A-C). These results indicated that *NF1* could partially regulate the

autophagic activity of BMSCs via the PI3K/AKT/mTOR signaling pathway.

Discussion

Data from the present study indicate that *NF1* regulated the autophagy of BMSCs. Overexpression of *NF1* promoted the autophagic activity of BMSCs, whilst autophagic activity was inhibited by the downregulation of *NF1*. Several studies have reported the effect of autophagy on *NF1*-deficient malignant peripheral nerve sheath tumors (MPNSTs) (26,27). In particular, Yang *et al* (26) found that *NF1*-deficient MPNST samples exhibit high mobility group protein A2




Figure 8. Results of transmission electron microscopy. Treatment with RAPA and 3-MA reversed the effects of *NF1*-siRNA and *NF1*-pcDNA3.0 transfection, respectively, on the autophagy activity of BMSCs (autophagosome was indicated by the arrows). Scale bars, 2 μ m. *NF1*, neurofibromin-1; si-, small interfering; NC, negative control; RAPA, rapamycin; 3-MA, 3-methyladenine.

(HMGA2) expression levels and that HMGA2 knockdown inhibited autophagy, which subsequently promotes MPNST cell death. However, to the best of our knowledge, few studies have reported the effects of *NF1* on autophagy in BMSCs. Tan *et al* (20) revealed that autophagic activity and osteogenic differentiation were significantly enhanced in *NF1*-overexpressing BMSCs, consistent with the results of the present study. However, Tan *et al* (20) only established *NF1*-overexpression BMSC models, which are different from the clinical situation in patients with *NF1* mutations, where the function of *NF1* is insufficient (8). Therefore, a cell model with inhibited expression of *NF1* can simulate the pathological conditions of *NF1* more closely compared with one with overexpression of *NF1*. The present study established cell models of BMSCs with the inhibition or overexpression of *NF1*, which is more translational for investigating the effects of *NF1* on the autophagy of BMSCs (26,27).

The present study also demonstrated that autophagy served a notable role in *NF1*-modulated osteogenic differentiation of BMSCs. Knockdown of *NF1* inhibited the autophagic activity of BMSCs and decreased the osteogenic differentiation of BMSCs whilst overexpression of *NF1*

resulted in the opposite effects. In addition, an autophagy activator (RAPA) and an autophagy inhibitor (3-MA) reversed the effects of *NF1*-knockdown and overexpression, respectively, on the osteogenic differentiation of BMSCs. A number of studies have demonstrated the involvement of *NF1* in osteogenic differentiation of BMSCs (8,10,11,28). In particular, a previous study demonstrated that downregulation and upregulation of *NF1* respectively inhibited and promoted osteogenic differentiation of BMSCs, respectively (13). Leskelä *et al* (8) cultured mesenchymal stem cells of patients with *NF1* and revealed impaired osteoblast differentiation. Conversely, loss of *NF1* resulted in increased osteoblast proliferation (10,11). Kolanczyk *et al* (10) established a mouse model with conditional inactivation of *NF1* in the limb skeleton and tested the effect of *NF1* on osteoblast proliferation. They revealed that the osteoblast cell division rate was significantly increased in inactivated *NF1* mutant cells when compared with that in controls. Additionally, other studies have demonstrated that autophagy can serve an important role in the osteogenic differentiation process (15,16,29-32). Wan *et al* (15) investigated the lumbar BMSCs of patients with osteoporosis and determined




Figure 9. AO staining and autophagic flux detection visualized under a fluorescence microscope. Magnification, x200. AO staining and autophagic flux detection visualized under a fluorescence microscope. In AO staining (A), autophagolysosomes were stained orange (indicated by the white arrows). The formation of autophagosomes were significantly increased in the *NF1*-siRNA + RAPA group compared with the *NF1*-siRNA, whilst it was significantly decreased in the *NF1*-pcDNA3.0 + 3-MA group compared with that in the *NF1*-pcDNA3.0 group. In autophagic flux detection (B), the GFP-LC3 combined autophagosomes were indicated by granular green fluorescence (indicated by the white arrows). Autophagic flux was significantly increased in the *NF1*-siRNA + RAPA group compared with the *NF1*-siRNA group, while it was significantly decreased in the *NF1*-pcDNA3.0 + 3-MA group compared with that in the *NF1*-pcDNA3.0 group. Results indicated that treatment with RAPA and 3-MA reversed the effects of *NF1*-siRNA and *NF1*-pcDNA3.0 transfection, respectively (indicated by the arrows). AO, acridine orange; *NF1*, neurofibromin 1; si-, small interfering; NC, negative control; RAPA, rapamycin; 3-MA, 3-methyladenine.

that the autophagy level in these BMSCs was significantly decreased, which was accompanied by inhibited osteogenic differentiation. Furthermore, it was identified that an autophagy activator (RAPA) significantly increased the osteogenic differentiation of BMSCs (15). Ma *et al* (29) also determined that the autophagy levels in young male mice were higher compared with those in aged male mice. In addition, treatment with an autophagy inhibitor significantly suppressed the osteogenic differentiation of BMSCs (29). Nuschke *et al* (30) found that autophagy levels in BMSCs were significantly increased during the early stages of osteogenic differentiation, whilst it was significantly decreased after differentiation into mature osteocytes. In addition, Liu *et al* (31), Gómez-Puerto *et al* (32) and Zhou *et al* (16) reported that autophagy served an important role in osteogenic differentiation of BMSCs. In brief, the majority of previous studies aforementioned reported that an increase in autophagic activity promotes osteogenic differentiation of BMSCs. However, the BMSCs used in these previous studies were purchased from patients without *NF1* mutation and with a native levels of *NF1* expression. The present study used *NF1*-knockdown and *NF1*-overexpressing BMSCs and confirmed the involvement of autophagy in *NF1*-modulated osteogenic differentiation of BMSCs.

The present study also indicated that the autophagic activity of BMSCs was partially regulated by *NF1* via the PI3K/AKT/mTOR signaling pathway. The PI3K/AKT/mTOR pathway was activated in *NF1*-knockdown BMSCs, whilst it was inhibited in *NF1*-overexpressing BMSCs. It has been previously reported that the PI3K/AKT/mTOR pathway serves a notable role in regulating autophagy (18,33,34). It is a classical signaling pathway for autophagy activation and the main gateway to autophagy (18,19). In particular, various studies have reported activation of the PI3K/AKT/mTOR signaling pathway in *NF1*-related MPNSTs (35,36). Previous studies by Tan *et al* (20) and Li *et al* (13), combined with the present study, demonstrate that regulation of autophagy facilitates *NF1*-mediated modulation of osteogenic differentiation of BMSCs via the PI3K/AKT/mTOR signaling pathway.

The mTORC1 signaling pathway has been reported to be an important regulator of autophagy (19). Unc-51-like autophagy activating kinase (ULK) is a key initiator of autophagy (37,38). Furthermore, mTORC1 inhibits the ULK complex by phosphorylating its components, including autophagy-related gene 13 and ULK1/2 (37,38). Additionally, mTORC1 regulates the Vps34 class III PI3K complex, which is needed for autophagosome formation (37,38). In the present

study, the autophagic activity in the *NF1*-pcDNA3.0 group was significantly decreased after an autophagy inhibitor (3-MA) was applied. It is known that 3-MA is an inhibitor of PI3K (39) and that it suppresses autophagy by inhibiting the class III PI3K (40). Additionally, 3-MA inhibits AKT by inhibiting the class I PI3K (40,41) and subsequently leads to mTORC1 inactivation (18). As aforementioned, mTORC1 signaling inhibits autophagosome formation (37,38). The inhibition of autophagy and osteogenic differentiation of BMSCs in the *NF1*-pcDNA3.0 + 3-MA group in the present study suggests that autophagy may partially regulate osteogenic differentiation of BMSCs through other mechanisms that are independent of mTOR signaling. It has been reported that AMP-activated protein kinase and the Wnt/ β -catenin signaling pathway may also mediate important roles in regulating autophagy in BMSCs (42,43). Therefore, further study is required to investigate the mechanism by which *NF1* modulates osteogenic differentiation of BMSCs through autophagy.

There are still some limitations in the present study. Firstly, our study only established BMSCs models with knockdown or overexpression of *NF1* by siRNA or pcDNA3.0, which is different from clinical condition (*NF1* mutation). Secondly, the present study is a cell experiment, further animal studies are required to confirm the role of autophagy on *NF1*-modulated growth of bone.

In conclusion, the present study demonstrated that autophagy played a significant role in *NF1*-mediated osteogenic differentiation of BMSCs. Downregulation of *NF1* inhibited autophagy to decrease osteogenic differentiation of BMSCs, whereas upregulation of *NF1* activated autophagy to increase osteogenic differentiation. *NF1* may partially regulate the autophagic activity of BMSCs via the PI3K/AKT/mTOR signaling pathway. The present study could guide a new direction for elucidating the etiology of *NF1*-associated skeletal abnormalities and provide a novel theoretical basis for the treatment of *NF1*.

Acknowledgements

Not applicable.

Funding

The present study was supported by funding from Guangzhou Women and Children's Medical Center/Guangzhou Institute of Pediatrics (grant no. IP-2019-001) and The National Nature Science Foundation of China (grant no. 81702116).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

Conceptualization, methodology, supervision and writing (review and editing) were performed by YQL, HWX and XML. Original draft and funding acquisition were performed by YQL. HWX and YQL provided resources. XML, MWZ,

JCL, ZY and YHL performed the experiments. YQL and MWZ analyzed the data. YQL and HWX confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Anderson JL and Gutmann DH: Neurofibromatosis type 1. *Handb Clin Neurol* 132: 75-86, 2015.
- Ferner RE and Gutmann DH: Neurofibromatosis type 1 (NF1): Diagnosis and management. *Handb Clin Neurol* 115: 939-955, 2013.
- Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL and Johnson KJ: Neurofibromatosis type 1. *Nat Rev Dis Primers* 3: 17004, 2017.
- Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, Upadhyaya M, Towers R, Gleeson M, Steiger C and Kirby A: Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. *J Med Genet* 44: 81-88, 2007.
- Feldman DS, Jordan C and Fonseca L: Orthopaedic manifestations of neurofibromatosis type 1. *J Am Acad Orthop Surg* 18: 346-357, 2010.
- Vitale MG, Guha A and Skaggs DL: Orthopaedic manifestations of neurofibromatosis in children: An update. *Clin Orthop Relat Res* 107-118, 2002.
- Shen MH, Harper PS and Upadhyaya M: Molecular genetics of neurofibromatosis type 1 (NF1). *J Med Genet* 33: 2-17, 1996.
- Leskelä HV, Kuorilehto T, Risteli J, Koivunen J, Nissinen M, Peltonen S, Kinnunen P, Messiaen L, Lehenkari P and Peltonen J: Congenital pseudarthrosis of neurofibromatosis type 1: Impaired osteoblast differentiation and function and altered NF1 gene expression. *Bone* 44: 243-250, 2009.
- Sharma R, Wu X, Rhodes SD, Chen S, He Y, Yuan J, Li J, Yang X, Li X, Jiang L, *et al*: Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice. *Hum Mol Genet* 22: 4818-4828, 2013.
- Kolanczyk M, Kossler N, Kuhnisch J, Lavitas L, Stricker S, Wilkening U, Manjubala I, Fratzl P, Sporle R, Herrmann BG, *et al*: Multiple roles for neurofibromin in skeletal development and growth. *Hum Mol Genet* 16: 874-886, 2007.
- Wu X, Estwick SA, Chen S, Yu M, Ming W, Nebesio TD, Li J, Yuan J, Kapur R, Ingram D, *et al*: Neurofibromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem/progenitor cells. *Hum Mol Genet* 15: 2837-2845, 2006.
- Wang W, Nyman JS, Ono K, Stevenson DA, Yang X and Eleftheriou F: Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I. *Hum Mol Genet* 20: 3910-3924, 2011.
- Li Y, Li J, Zhou Q, Liu Y, Chen W and Xu H: mTORC1 signaling is essential for neurofibromatosis type I gene modulated osteogenic differentiation of BMSCs. *J Cell Biochem* 120: 2886-2896, 2019.
- Reggiori F and Klionsky DJ: Autophagy in the eukaryotic cell. *Eukaryot Cell* 1: 11-21, 2002.
- Wan Y, Zhuo N, Li Y, Zhao W and Jiang D: Autophagy promotes osteogenic differentiation of human bone marrow mesenchymal stem cell derived from osteoporotic vertebrae. *Biochem Biophys Res Commun* 488: 46-52, 2017.
- Zhou Z, Shi G, Zheng X, Jiang S and Jiang L: Autophagy activation facilitates mechanical stimulation-promoted osteoblast differentiation and ameliorates hindlimb unloading-induced bone loss. *Biochem Biophys Res Commun* 498: 667-673, 2018.

17. Lim HJ, Crowe P and Yang JL: Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. *J Cancer Res Clin Oncol* 141: 671-689, 2015.
18. Heras-Sandoval D, Perez-Rojas JM, Hernandez-Damian J and Pedraza-Chaverri J: The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. *Cell Signal* 26: 2694-2701, 2014.
19. Rabanal-Ruiz Y, Otten EG and Korolchuk VI: mTORC1 as the main gateway to autophagy. *Essays Biochem* 61: 565-584, 2017.
20. Tan Q, Wu JY, Liu YX, Liu K, Tang J, Ye WH, Zhu GH, Mei HB and Yang G: The neurofibromatosis type I gene promotes autophagy via mTORC1 signalling pathway to enhance new bone formation after fracture. *J Cell Mol Med* 24: 11524-11534, 2020.
21. Zhao F, Feng G, Zhu J, Su Z, Guo R, Liu J, Zhang H and Zhai Y: 3-Methyladenine-enhanced susceptibility to sorafenib in hepatocellular carcinoma cells by inhibiting autophagy. *Anticancer Drugs* 32: 386-393, 2021.
22. Song C, Song C and Tong F: Autophagy induction is a survival response against oxidative stress in bone marrow-derived mesenchymal stromal cells. *Cytotherapy* 16: 1361-1370, 2014.
23. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
24. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, *et al*: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy* 12: 1-222, 2016.
25. Shibutani ST, Saitoh T, Nowag H, Münz C and Yoshimori T: Autophagy and autophagy-related proteins in the immune system. *Nat Immunol* 16: 1014-1024, 2015.
26. Yang K, Guo W, Ren T, Huang Y, Han Y, Zhang H and Zhang J: Knockdown of HMGA2 regulates the level of autophagy via interactions between MSI2 and Beclin1 to inhibit NF1-associated malignant peripheral nerve sheath tumour growth. *J Exp Clin Cancer Res* 38: 185, 2019.
27. Lopez G, Torres K, Liu J, Hernandez B, Young E, Belousov R, Bolshakov S, Lazar AJ, Slopis JM, McCutcheon IE, *et al*: Autophagic survival in resistance to histone deacetylase inhibitors: Novel strategies to treat malignant peripheral nerve sheath tumors. *Cancer Res* 71: 185-196, 2011.
28. de la Croix Ndong J, Stevens DM, Vignaux G, Uppuganti S, Perrien DS, Yang X, Nyman JS, Harth E and Eleftheriou F: Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Ox^{-/-} mice. *J Bone Miner Res* 30: 55-63, 2015.
29. Ma Y, Qi M, An Y, Zhang L, Yang R, Doro DH, Liu W and Jin Y: Autophagy controls mesenchymal stem cell properties and senescence during bone aging. *Aging Cell* 17: e12709, 2018.
30. Nuschke A, Rodrigues M, Stolz DB, Chu CT, Griffith L and Wells A: Human mesenchymal stem cells/multipotent stromal cells consume accumulated autophagosomes early in differentiation. *Stem Cell Res Ther* 5: 140, 2014.
31. Liu X, Wang Y, Cao Z, Dou C, Bai Y, Liu C, Dong S and Fei J: Staphylococcal lipoteichoic acid promotes osteogenic differentiation of mouse mesenchymal stem cells by increasing autophagic activity. *Biochem Biophys Res Commun* 485: 421-426, 2017.
32. Gomez-Puerto MC, Verhagen LP, Braat AK, Lam EW, Coffey PJ and Lorenowicz MJ: Activation of autophagy by FOXO3 regulates redox homeostasis during osteogenic differentiation. *Autophagy* 12: 1804-1816, 2016.
33. Chang H, Li X, Cai Q, Li C, Tian L, Chen J, Xing X, Gan Y, Ouyang W and Yang Z: The PI3K/Akt/mTOR pathway is involved in CVB3-induced autophagy of HeLa cells. *Int J Mol Med* 40: 182-192, 2017.
34. Gao Y, Zhang Y and Fan Y: Eupafolin ameliorates lipopolysaccharide-induced cardiomyocyte autophagy via PI3K/AKT/mTOR signaling pathway. *Iran J Basic Med Sci* 22: 1340-1346, 2019.
35. Schulte A, Ewald F, Spyra M, Smit DJ, Jiang W, Salamon J, Jucker M and Mautner VF: Combined targeting of AKT and mTOR inhibits proliferation of human NF1-associated malignant peripheral nerve sheath tumour cells in vitro but not in a xenograft mouse model in vivo. *Int J Mol Sci* 21: 1548, 2020.
36. Li XX, Zhang SJ, Chiu AP, Lo LH, Huang J, Rowlands DK, Wang J and Keng VW: Targeting of AKT/ERK/CTNNB1 by DAW22 as a potential therapeutic compound for malignant peripheral nerve sheath tumor. *Cancer Med* 7: 4791-4800, 2018.
37. Kim YC and Guan KL: mTOR: A pharmacologic target for autophagy regulation. *J Clin Invest* 125: 25-32, 2015.
38. Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, Miura Y, Iemura S, Natsume T, Takehana K, Yamada N, *et al*: Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. *Mol Biol Cell* 20: 1981-1991, 2009.
39. Blommaert EF, Krause U, Schellens JP, Vreeling-Sindelarova H and Meijer AJ: The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. *Eur J Biochem* 243: 240-246, 1997.
40. Petiot A, Ogier-Denis E, Blommaert EF, Meijer AJ and Codogno P: Distinct classes of phosphatidylinositol 3'-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. *J Biol Chem* 275: 992-998, 2000.
41. Wu YT, Tan HL, Shui G, Bauvy C, Huang Q, Wenk MR, Ong CN, Codogno P and Shen HM: Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. *J Biol Chem* 285: 10850-10861, 2010.
42. Li Y, Su J, Sun W, Cai L and Deng Z: AMP-activated protein kinase stimulates osteoblast differentiation and mineralization through autophagy induction. *Int J Mol Med* 41: 2535-2544, 2018.
43. Chen X, Sun K, Zhao S, Geng T, Fan X, Sun S, Zheng M and Jin Q: Irisin promotes osteogenic differentiation of bone marrow mesenchymal stem cells by activating autophagy via the Wnt/ β -catenin signal pathway. *Cytokine* 136: 155292, 2020.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.